Indication
Weight loss management for obese patient (body mass index 30 or greater)
This indication designates chronic clinical intervention for adult patients diagnosed with obesity, defined as having a body mass index of 30 kg/m² or greater. Read more about Weight loss management for obese patient (body mass index 30 or greater)
106 drugs 60 manufacturers
Drugs that treat it
Common Weight loss management for obese patient (body mass index 30 or greater) therapies.
CONTRAVE (naltrexone HCl/bupropion HCl)
AMPHETAMINE SULFATE
WEGOVY (semaglutide)
EVEKEO (amphetamine sulfate)
ZEPBOUND (tirzepatide)
AMPHETAMINE SULFATE
PHENTERMINE HCL
AMPHETAMINE SULFATE
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonThis indication designates chronic clinical intervention for adult patients diagnosed with obesity, defined as having a body mass index of 30 kg/m² or greater.
Obesity is a complex, multifactorial, relapsing chronic metabolic disease characterized by excessive adiposity resulting from sustained energy imbalance.
This pathological accumulation of adipose tissue induces systemic neuroendocrine dysfunction, adipokine dysregulation, and persistent low-grade inflammation.
Left unmanaged, it significantly impairs multiple organ systems and increases the risk of chronic comorbidities, including atherosclerotic cardiovascular disease, hypertension, type 2 diabetes mellitus, dyslipidemia, and obstructive sleep apnea.
- fda.gov
This indication designates chronic clinical intervention for adult patients diagnosed with obesity, defined as having a body mass index of 30 kg/m² or greater
- nih.gov
This indication designates chronic clinical intervention for adult patients diagnosed with obesity, defined as having a body mass index of 30 kg/m² or greater
- nih.gov
Obesity is a complex, multifactorial, relapsing chronic metabolic disease characterized by excessive adiposity resulting from sustained energy imbalance
- nih.gov
Obesity is a complex, multifactorial, relapsing chronic metabolic disease characterized by excessive adiposity resulting from sustained energy imbalance This pathological accumulation of adipose tissue induces systemic neuroendocrine dysfunction, adipokine dysregulation, and persistent low-grade inflammation Left unmanaged, it significantly impairs multiple organ systems and increases the risk of chronic comorbidities, including atherosclerotic cardiovascular disease, hypertension, type 2 diabet...
- nih.gov
Left unmanaged, it significantly impairs multiple organ systems and increases the risk of chronic comorbidities, including atherosclerotic cardiovascular disease, hypertension, type 2 diabetes mellitus, dyslipidemia, and obstructive sleep apnea
Personalize your experience
Follow Weight loss management for obese patient (body mass index 30 or greater) and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.